Shots:
- Eli Lilly has reported long-term data from the P-III (LUCENT-3) OLE study of P-III (LUCENT-1 & LUCENT-2) trials, evaluating the efficacy & safety of Omvoh (mirikizumab-mrkz) in mod. to sev. active ulcerative colitis pts over an additional 3yrs., totaling ~4yrs. of treatment
- In LUCENT-3, among pts who achieved clinical remission with Omvoh at 1yr. in LUCENT-2 study, 78% remained corticosteroid-free & 78% maintained long-term clinical remission, while 81% sustained endoscopic remission
- Also, 90% achieved IBDQ remission, 66% showed histological-endoscopic mucosal improvement, & 93% had ≥3-point UNRS reduction, with 74% reaching UNRS = 0 or 1; data to be presented at UEG’25
Ref: Eli Lilly | Image: Eli Lilly| Press Release
Related News:- Eli Lilly’s Inluriyo (Imlunestrant) Receives the US FDA’s Approval for ESR1-mutated Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
